Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

06/30/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

This week in Talking Therapeutics, Dr Jennings pays homage to the creation of insulin and focuses on current issues that reduce access to this life-saving treatment.

This week in Talking...

06/30/2021

Pharmacy Learning Network

Talking Therapeutics

‘Tis the Season for a Festive Direct Oral Anticoagulant Update

12/22/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings provides an update on direct oral anticoagulants, reviewing a recent study that compared the outcomes of patients taking rivaroxaban vs apixaban.

Dr Jennings provides an update...

12/22/2021

Pharmacy Learning Network

Talking Therapeutics

News Roundup: Paxlovid for Omicron, USPSTF Recommendations

08/25/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings highlights news from the past week, including data on Paxlovid's efficacy against the Omicron variant and updated statin recommendations from the US Preventive Services Task Force.

Dr Jennings highlights news from...

08/25/2022

Pharmacy Learning Network

Talking Therapeutics

New Study Shows Cardiac Risks With Over-the-Counter Opioids

06/09/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In light of new data showing over-the-counter opioids were associated with cardiac arrhythmias, Dr Jennings calls for efforts to counsel patients accordingly.

In light of new data showing...

06/09/2023

Pharmacy Learning Network

Commentary

Achieving Victory Over Vitiligo: JAK Inhibitor Promotes Repigmentation

05/31/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this commentary, Douglas L. Jennings, PharmD, reviews findings from a study which tested the use of oral ritlecitinib in patients with nonsegmental vitiligo.

In this commentary, Douglas L....

05/31/2023

First Report Managed Care

Talking Therapeutics

An Antiplatelet Update

07/21/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

This week, Dr Jennings reviews two new papers that were recently published regarding antiplatelet therapy in acute coronary syndrome.

This week, Dr Jennings reviews...

07/21/2021

Pharmacy Learning Network

Talking Therapeutics

Navigating Muddy Waters of COVID-19 Drug-Drug Interactions

03/16/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings discusses COVID-19 treatment efficacy as new variants emerge, as well as the management of drug-drug interactions between these treatments and other medications.

Dr Jennings discusses COVID-19...

03/16/2022

Pharmacy Learning Network

Talking Therapeutics

Targeting Doses of Guideline-Directed Medical Therapy in Heart Failure

10/20/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings shares a new study which suggests lower doses of guideline-directed medical therapy might still produce a significant benefit for patients.

Dr Jennings shares a new study...

10/20/2022

Pharmacy Learning Network

Talking Therapeutics

Cefepime vs Piperacillin-Tazobactam for Hospital-Acquired Infection

11/04/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s issue, we discuss the ACORN study, which compared the outcomes of cefepime vs pip-tazo in patients with hospital-acquired infections.

In this week’s issue, we discuss...

11/04/2023

Pharmacy Learning Network

Talking Therapeutics

Optimizing Medication Dosing After Heart Transplantation

12/21/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings walks through findings from a new study comparing 2 dosing regimens of mycophenolate mofetil in patients who had heart transplant surgery.

Dr Jennings walks through...

12/21/2022

Pharmacy Learning Network